Rationale The endogenous oxytocin system has emerged as an inhibitor of drug-seeking and stress in preclinical models. Objectives The goal of this study was to examine whether systemic oxytocin administration attenuated methamphetamine (METH)-seeking in rats pre-exposed to a predator odor threat. Methods In Experiment 1, rats were exposed for 5 days to the predator odor, 2,5-dihydro-2,4,5-trimethylthiazoline (TMT), or saline before METH self-administration began. After extinction training, rats were injected with 1 mg/kg, ip oxytocin (OXT) or saline 30 min before a cue-induced reinstatement test followed by re-extinction and a TMT-induced reinstatement test. In Experiment 2, TMT pre-exposure was followed by 10 days of 1 mg/kg OXT or saline injections before METH self-administration, extinction, and a TMT-induced reinstatement test. Results In Experiment 1, TMT pre-exposed rats that were injected with saline 30 min before reinstatement exhibited greater drug-seeking induced by conditioned cues or TMT than that exhibited by saline pre-exposed rats. A single injection of OXT 30 min before reinstatement suppressed METHseeking in both saline-and TMT pre-exposed rats. In Experiment 2, TMT pre-exposed rats that received saline injections for 10 days prior to METH self-administration exhibited enhanced drug-seeking induced by TMT during stressinduced reinstatement. OXT injections for 10 days prior to METH self-administration blocked only the stress-induced exacerbation of drug-seeking in TMT pre-exposed rats. Conclusions These results support further research on the development of oxytocin as a novel therapeutic drug that has enduring effects on drug-seeking exacerbated by stress.
Introduction
Posttraumatic stress disorder (PTSD) is a debilitating anxiety disorder with three major symptom clusters: persistent avoidance of trauma-related stimuli, hyperarousal, and intrusive reexperiencing of the traumatic event (American Psychiatric Association 2013). PTSD is often complicated by the presence of concurrent substance use disorder (SUD). Individuals with PTSD report a rate of substance dependence that is 2-3 times higher than that of those without PTSD (Cottler et al. 1992; Jacobsen et al. 2001; Kessler et al. 1995) . Moreover, clinical studies have demonstrated that methamphetamine (METH) is twice as likely to be used in individuals with concurrent PTSD than in trauma-exposed individuals without PTSD (Smith et al. 2010) . These studies are consistent with a wider body of literature reporting a strong relationship between PTSD and substance abuse (Back et al. 2000; Brady 2001; Cottler et al. 1992; Khoury et al. 2010) .
Treatment of PTSD symptoms has been reported to have a greater impact on improving SUD symptoms than vice versa (Hien et al. 2010) . During the past decade, the endogenous neuropeptide, oxytocin (OXT), has been shown to exert Electronic supplementary material The online version of this article (doi:10.1007/s00213-015-4184-7) contains supplementary material, which is available to authorized users. potent anxiolytic, anti-fear, and anti-stress effects in humans (Heinrichs and Domes 2008; Kirsch et al. 2005 ) and in animals (Neumann and Landgraf 2012; Ring et al. 2006; Viviani et al. 2011) . Based on these and other findings, intra-nasal OXT has been promoted as a potential early intervention to prevent the development of PTSD after trauma in humans (Frijling et al. 2014; Frijling et al. 2015) . Similarly, based on preclinical studies, OXT has emerged as a potential treatment for substance use disorders (McGregor and Bowen 2012; Sarnyai 2011) . Systemic administration of OXT inhibits METH-induced hyperactivity and conditioned place preference (Baracz et al. 2012; Carson et al. 2010; Qi et al. 2009 ) and dose-dependently decreases the motivation to selfadminister METH on a progressive ratio schedule (Carson et al. 2010) . Furthermore, OXT decreases drug-seeking induced by a METH prime or the anxiogenic drug, yohimbine (Carson et al. 2010; Cox et al. 2013) . However, the effects of OXT in a preclinical model of repeated stress combined with drug selfadministration (SA) and seeking has not been investigated previously.
Preclinical models of PTSD pathology involve exposing rodents to various stressors in order to elicit behavioral and biological responses that simulate those observed in humans (Pitman et al. 2012; Goswami et al. 2013) . A history of stress can alter responses to substances of abuse. Recent studies have demonstrated that footshockinduced stress increased alcohol consumption (Meyer et al. 2013 ) whereas maternal separation in early life increased METH self-administration (Lewis et al. 2015) . Another PTSD model, single prolonged stress, enhanced locomotor sensitization to cocaine but did not alter cocaine SA (Eagle et al. 2015) and had mixed effects on METH-or amphetamine-induced behavioral sensitization (Eagle and Perrine 2013; Toledano et al. 2013) . Predator odors, such as 2,5-dihydro-2,4,5-trimethylthiazoline (TMT), are ecologically relevant stressors that reliably induce hyperarousal, a long-lasting avoidance of traumarelated cues, and dysregulation of the hypothalamicpituitary-adrenal (HPA) axis (Fendt et al. 2005; Thomas et al. 2006) . Repeated TMT exposure produces anxietylike behaviors and long-lasting avoidance of traumarelated cues (Ojo et al. 2014) . However, the effects of prior predator odor exposure on drug SA and reinstatement of drug-seeking has not been investigated previously. Thus, in this study, we investigated whether repeated TMT exposure in one environment (activity chambers) altered the response of rats to (1) METH SA and (2) reinstatement induced by re-experiencing the predator odor in the operant chambers previously associated with METH.
Because the suppressive effects of OXT on the reinstatement of METH-seeking induced by various stimuli have been established (Carson et al. 2010; Cox et al. 2013; Hicks et al. 2014 ), first we examined the effects of an acute dose of systemic OXT on conditioned cue-induced reinstatement followed by TMT-induced reinstatement of METH-seeking in rats with or without a history of TMT pre-exposure. Second, we examined whether daily, systemic OXT injections immediately after TMT exposure and before METH SA would prevent subsequent susceptibility to TMT-induced drug-seeking. The latter OXT paradigm is based on evidence that 10 days of daily OXT injections in adolescent rats suppressed alcohol consumption (Bowen et al. 2011) or drug-seeking induced by a METH prime (Hicks et al. 2014) weeks after the end of OXT administration.
Experimental procedures Animals
Adult male Sprague-Dawley rats (N = 64; Charles River Laboratories, Wilmington, MA) weighing 300-325 g at the start of the experiment were housed individually on a reverse light/ dark cycle (6 a.m-6 p.m.). All animal use protocols were approved by the Institutional Animal Care and Use Committee of the Medical University of South Carolina and the USAMRMC ACURO. All experiments were performed in accordance with the NIH Guide for the Care and Use of Laboratory Animals (2010). Animals were divided into two cohorts (n = 16 per cohort) in each of two experiments and weighed daily. One rat in Experiment 1 died prior to the start of METH self-administration (SA), and one rat in Experiment 2 died during METH SA, and both were eliminated from the dataset.
IV catheter surgery
Intravenous catheters were implanted into the right jugular vein as described previously (Cox et al. 2013) . Briefly, rats were anesthetized with ketamine (66 mg/kg, ip) and xylazine (1.33 mg/kg, ip), followed by equithesin and ketorolac (2.0 mg/kg, ip.). The catheters were attached to cannulae that were secured to a back mount cannula connector pedestal (Plastics One, Roanoke, VA). During the 3-5 day surgical recovery, rats were infused with 10 mg/0.1 ml of cefazolin and 0.05 ml of Taurolidine-Citrate Catheter Solution (TCS; Access Technologies, Skokie, IL) i.v. daily.
Predator odor exposure and locomotor activity testing
Baseline open field behavior was assessed during the dark cycle under red light conditions 24 h prior to i.v. catheterization. Rats were placed individually in a Digiscan Animal Activity Monitor (Accuscan Instruments, Inc., Columbus, OH) for 15 min. during which locomotor activity was recorded and quantified by Versamax software. Then after 3-5 days of recovery from surgery, rats were individually exposed to either 10 ul of a 1 % sol uti on of 2,5-dihydro-2, 4,5-trimethylthiazonline (TMT; Phero Tech Inc., Delta, BC, Canada) diluted in saline or the saline vehicle on a filter paper in a weigh boat in the center of the activity chamber for 15 min per day for 5 days (between 0900 and 1030 hours). The salineexposed group was tested and removed from the testing room each day before the second group was exposed to TMT to minimize the potential for unintentional exposure to the predator odor. Locomotor activity was recorded as described above for 15 min immediately following removal of the TMT or saline. The chambers were cleaned thoroughly with 70 % ethanol and air-dried after each animal was removed to eliminate scent cues. On day 1 and day 5 of the protocol, each rat was removed from the chamber at the end of the 15 min exposure, and 0.2 ml of blood was immediately collected via their i.v. catheter into tubes containing 100 U heparin for determination of corticosterone (CORT) levels. Blood samples were taken 2-4 h after the start of the dark cycle.
Corticosterone measurements
Blood was collected in tubes containing 100 U heparin. Samples were centrifuged at 2000×g for 20 min, plasma collected, and samples stored at −20°C before analysis using a I 125 Corticosterone radioimmunoassay Kit (MP Biomedicals, Santa Ana, CA).
Experimental design
All rats underwent similar experimental conditions prior to being separated into the two experiments described below.
Experiment 1: administration of OXT 30 min prior to reinstatement testing Figure 1 details the design for Experiment 1. Two days after the last TMT exposure, METH self-administration (SA) was initiated as described previously (Cox et al. 2013) . Each rat was placed into a self-administration chamber (Med Associates, St. Albans, VT) and allowed to lever press for 0.02 ug methamphetamine HCl in 50 ul sterile saline (Sigma-Aldrich Co., St. Louis, MO) on a fixed ratio 1 schedule for 120 min for 14 consecutive days (Roth and Carroll 2004; Rocha and Kalivas 2010) . Each infusion was paired with a compound conditioned stimulus complex (light plus tone) that consisted of illumination of a white stimulus light directly above the active lever and a tone (2 kHz, 15 dB above ambient noise). Immediately following the last SA session, rats underwent 2 h daily extinction training sessions in which responding on the previously active and inactive levers was recorded but had no programmed consequences. No light and tone cues were activated during extinction. Extinction criteria consisted of two consecutive days of less than 20 presses on the previously active lever (achieved within 6-7 days).
One day after extinction training, all rats were injected with either 1 mg/kg, ip. OXT, a dose that decreases METH-seeking (Carson et al. 2010; Cox et al. 2013 ), or saline. Thirty minutes later, at a time when the locomotor suppressive effects of OXT had diminished (Zhou et al. 2015) , the rats were re-exposed to the operant chamber for a 2-h cue-induced reinstatement test in which the compound light and tone stimuli were presented with each active lever press. Then, the rats were re-extinguished as described above followed by testing for TMT-induced reinstatement of METH-seeking. Rats were injected with either 1 mg/kg, i.p. OXT or saline 30 min before exposure to 1 % TMT for the first 15 min of the 2-h reinstatement Fig. 1 Experimental timeline. For Experiment 1, the experimental groups were as follows: saline-pre-exposure (PE) + saline (saline-PE sal; n = 8), saline-PE + oxytocin (OXT) (saline-PE OXT; n = 7), TMT-PE + saline (TMT-PE sal; n = 8), TMT-PE + OXT (TMT-PE OXT; n = 8).
For Experiment 2, the experimental groups were as follows: saline-PE + 10 days saline (saline-PE 10-day sal; n = 7), saline-PE + 10 days OXT (saline-PE 10-day OXT; n = 8), TMT-PE + 10 days saline (TMT-PE 10-day sal; n = 8), TMT-PE + 10 days OXT (TMT-PE 10-day OXT; n = 8) test. The groups were not counter-balanced to provide a group of pure saline controls for future molecular analyses. The complex conditioned stimulus was not presented during extinction or the TMT-induced reinstatement test. Active (right) and inactive (left) lever presses were recorded during the entire 2 h of the reinstatement tests but had no programmed consequences. The rats were decapitated without anesthesia, the brains were extracted, and trunk blood was collected immediately after the TMT-induced reinstatement test.
Experiment 2: repeated administration of OXT prior to METH SA Figure 1 details the design for Experiment 2. One day after the last TMT exposure, the rats were injected with 1 mg/kg i.p. OXT or saline daily for ten consecutive days. The day after the last injection, rats initiated METH SA followed by extinction training to the criteria described above (achieved in 6 days). The day after the end of extinction training, all rats were re-exposed to the operant chamber for a 2-h reinstatement test in which they were exposed to 1 % TMT for the first 15 min of the 2-h test as described above. The rats were decapitated without anesthesia, the brains were extracted, and trunk blood was collected immediately after the TMT-induced reinstatement test.
Statistical analysis
All data were analyzed with two-way ANOVAs with or without repeated measures using Graph Pad Prism. Data yielding a significant interaction were further analyzed with Bonferronicorrected tests. Unpaired t tests were used post hoc to compare the ratio of OXT-induced changes in Sal-PE vs. TMT-PE groups in Experiment 1.
Results

TMT produces avoidance and dysregulation of the HPA axis
Qualitative observations indicated that rats exposed to 1 % TMT for 5 days moved from corner to corner of the activity chamber (thigmotaxis) and did not freeze in the presence of the predator odor. Locomotor activity for 15 min after the TMT or saline was removed, and CORT measurements from blood collected immediately after locomotor testing for rats in experiments 1 and 2 did not differ between groups, so the data were pooled. Figure 2 illustrates the open field behavior (2A), total activity (2B), weight gain (2C), and CORT levels (2D) for all rats before and after TMT pre-exposure (PE). A twoway RM ANOVA of the open field data revealed a significant day × TMT pre-exposure interaction (F (2,122) = 49.6, p < 0.0001). No significant differences in baseline anxietylike behavior were observed between groups as measured by performance in the open field (Fig. 2a) . However, TMT-PE rats spent significantly less time in the center of the open field than the saline-PE rats on both day 1 and day 5 (p < 0.0001, Fig. 2a ), and they demonstrated significantly less overall activity (total distance traveled) on day 5 (Interaction F (2, 122) = 27.05, p < 0.0001; Bonferroni p < 0.0001, Fig. 2b ). Although the average weight of the rats randomly selected for the saline-PE (342.3+/−2.3, n = 31) and TMT-PE (349.8+/ −3.8, n = 32) groups did not differ on baseline day 1 (Supplemental Fig. 1A ), TMT exposure for 5 days resulted in significantly less weight gain for TMT-PE rats than for saline-PE rats ( Fig. 2c ; t (1,61) = 8.058, p < 0.0001). With regard to CORT levels, a two-way RM ANOVA revealed a significant day × TMT pre-exposure interaction [ Fig. 2d ; F (2,120) = 34.88, p < 0.0001; two samples lost]. Bonferroni-adjusted comparisons showed that while there were no significant differences in baseline CORT levels, TMT-PE rats had significantly higher CORT levels than saline-PE rats immediately following exposure on day 1 (p < 0.0001) and day 5 (p = 0.0001). Although TMT-induced CORT levels decreased between days 1 and day 5 (p < 0.001), CORT levels on both days were significantly higher than baseline. Further, the ratio between TMT-PE and SAL-PE groups on day 1 is 4.16 whereas the ratio on day 5 is 5.13, suggesting that there was an overall habituation of both groups to the environment and testing procedures.
Experiment 1: a single dose of systemic OXT blocks reinstatement of METH-seeking regardless of stress pre-exposure
Despite the reduced weight gain seen in TMT-PE rats during stress exposure, there were no significant differences in body weight between saline-PE rats and TMT-PE rats during METH SA (Supplemental Fig. 1B ). TMT pre-exposure had no significant effect on active or inactive lever presses (Fig. 3a) or infusions ( Fig. 3b) during METH SA. Further, there were no significant differences in the average number of lever presses between groups during the last 2 days of extinction (Fig. 3c) or the number of days to reach extinction criterion (Supplemental Fig. 2 ). In contrast, A two-way ANOVA of the effects of OXT on cue-induced reinstatement revealed that there Fig. 3 METH self-administration, extinction, and TMT-induced reinstatement in TMT-PE and saline-PE rats. a METH self-administration over 14 days: active lever presses (black) and inactive lever presses (grey). b Average number of infusions received during METH SA for saline-PE and TMT-PE rats. c Average number of previously active lever presses during the last 2 days of extinction (left) and cue-induced reinstatement for TMT-PE and saline-PE rats injected with saline or OXT 30 min prior to reinstatement testing (right). d Average number of previously active lever presses during the last 2 days of extinction (left) and TMT-induced reinstatement for TMT-PE and saline-PE rats injected with saline or OXT 30 min prior to reinstatement testing (right). Mean +/ − SEM; ****p < 0.0001, n = 7-8 per group was a significant drug treatment × stress pre-exposure interaction (F (1,12) = 9.134, p < 0.05, the data from one cohort was lost due to experimental error, leaving n = 4 per group). A Bonferroni-adjusted comparison showed that TMT-PE rats pressed the active levers significantly more during the cue-induced reinstatement test than saline-PE rats when rats were injected with saline 30 min before testing (p < 0.01, Fig. 3c ). Administration of OXT 30 min before testing blocked the cue-induced reinstatement of drug-seeking in both TMT-PE (p < 0.0001) and saline-PE groups (p < 0.001, Fig. 3c ). However, there was no difference in the amplitude of OXT-induced suppression in Sal-PE vs. TMT-PE rats (t (6) = 0.9; p = 0.4). The rats underwent further extinction training to criterion following the cue-induced reinstatement test. There were no significant differences in the number of lever presses between groups during the last 2 days of extinction in animals with a history of METH (Fig. 3d) . Further, a two-way ANOVA revealed a significant drug treatment × stress pre-exposure interaction (F ( 1 , 2 7 ) = 31.10; p < 0.05, n = 8 per group) for the TMT-induced reinstatement data. Bonferroni-adjusted comparisons revealed significantly greater TMT-induced reinstatement in the TMT-PE group than in the saline-PE group (p < 0.0001, Fig. 3d ). Injection of OXT 30 min prior to testing blocked the ability of TMT to elicit reinstatement in both TMT-PE rats and saline-PE rats (p < 0.0001, Fig. 3d ). Further, there was a significant difference in the amplitude of OXTinduced suppression in Sal-PE vs. TMT-PE rats (t (12) = 2.2; p = 0.05). A two-way ANOVA revealed a significant interaction between stress pre-exposure and drug treatment for plasma CORT levels derived from trunk blood collected 2 h after TMT exposure (F (1,27) = 4.8. p < 0.05). A Bonferroniadjusted comparison revealed that plasma CORT levels in Sal-PE or TMT-PE rats injected with saline before the reinstatement test were not different from each other. However, plasma CORT levels in TMT-PE rats injected with OXT were significantly greater than those of TMT-PE rats injected with saline (***p < 0.001) and SAL-PE rats injected with OXT ( # p < 0.05, Fig. 4 ).
Experiment 2: repeated systemic OXT selectively blocks reinstatement of METH-seeking in rats with a history of stress exposure
In Experiment 2, 1 day after the last TMT exposure, rats received an injection of either 1 mg/kg, i.p. OXT or saline for 10 days. Two-way repeated measures ANOVA for body weight gain over time revealed an interaction for groups × time (F (39,351) = 4.37, p < 0.0001). The body weights of TMT-PE rats remained significantly lower than SAL-PE rats during the first 5 days of the 10-day saline injection period (day 1, 5 TMT-PE 10-day Sal vs. saline-PE 10-day Sal, p < 0.01); however, their average weight was not significantly different than the SAL-PE rats by day 10 of the saline injections (Fig. 5a) . Similarly, the body weights of these two groups did not differ during METH SA, although neither group gained weight. In contrast, regardless of TMT pre-exposure, OXT-injected rats gained significantly less weight during the 10-day OXT or Sal injection period ( Fig. 5a ; saline-PE 10-day OXT vs. saline-PE 10-day Sal day 10, p < 0.001; TMT-PE 10-day OXT day 10 vs. TMT-PE 10-day Sal, p < 0.05). The effect of OXT on weight persisted throughout METH SA ( Fig. 5a ; saline-PE 10-day Sal vs. saline-PE 10-day OXT day 1, 7, 14, p < 0.001; TMT-PE 10-day Sal vs. TMT-PE 10-day OXT on METH SA day 1, p < 0.05; TMT-PE 10-day Sal vs. TMT-PE 10-day OXT on METH SA day 7, p < 0.01).
Neither TMT pre-exposure or repeated OXT injections had a significant effect on the acquisition or maintenance of METH SA, as no group differences were observed in active or inactive lever presses (Fig. 5b) . In addition, despite the differences in weight gain seen in the OXT-injected animals, no significant differences were observed in total METH intake (not shown) or METH intake by body weight ( Fig. 5c ; calculated as the number of METH infusions multiplied by the individual rat's body weight, divided by the dosage of METH per infusion).
There were no significant group differences in the number of days to reach extinction criterion (Supplemental Fig. 3 ) or in the number of active lever presses during the last 2 days of extinction (Fig. 5d) . A two-way ANOVA revealed a significant drug treatment × stress pre-exposure interaction (F (1, 27) = 22.72, p < 0.0001). Bonferroni-adjusted comparisons revealed that reinstatement in TMT-PE rats was significantly greater than that of saline-PE rats in groups injected with saline for 10 days prior to METH SA (p < 0.01, Fig. 5d ). Injection with 1 mg/kg, i.p. OXT for 10 days prior to METH SA selectively blocked the enhanced TMT-induced reinstatement (p < 0.0001, Fig. 5d ) and caused a non-significant reduction in reinstatement compared to saline-PE 10-day OXT rats (p = 0.07).
A two-way ANOVA revealed a main effect of 10-day drug treatment (F (1,27) = 18, p < 0.001) on plasma CORT levels derived from trunk blood collected 2 h after TMT exposure in Sal-PE or TMT-PE rats. CORT levels in 10-day OXT-injected rats were significantly lower than those in saline-injected rats regardless of TMT pre-exposure (Fig. 6) .
Discussion
This is the first study to demonstrate that peripheral administration of OXT suppresses drug-seeking exacerbated by preexposure to an aversive predator odor. Exposure to TMT caused rats to avoid the center of the open field on days 1 and day 5 after the TMT had been removed, suppressed weight gain, and caused increased plasma CORT levels, confirming its utility as a predator threat. Further, TMT itself induced reinstatement in rats whether or not they had been Fig. 6 Plasma levels of corticosterone derived from trunk blood immediately following 2-h TMT-induced reinstatement test in Experiment 2. 10-day saline vs. 10-day OXT main effect ***p < 0.001 (n = 8 per group) Fig. 5 Effects of 10 days of OXT injections on weight gain, METH selfadministration, extinction, and TMT-induced reinstatement in TMT-PE and saline-PE rats. a Body weight gain of TMT-PE and saline-PE rats during the 10 days of saline or OXT injections and during METH selfadministration. For clarity, only data from days 1, 5, and 10 of the saline or OXT injection duration and days 1, 7, and 14 of METH SA are illustrated (*p < 0.05,***p < 0.001 saline-PE 10-day Sal vs. Sal-PE 10-day OXT,^p < 0.05 Sal-PE 10-day Sal vs. TMT-PE 10-d Sal;
# p < 0.05, ## p < 0.01 TMT-PE 10-day Sal vs. TMT-PE 10-day OXT). b Average number of active lever presses (black) or inactive lever presses (grey) during the 14 days of METH self-administration. c Average number of METH infusions/animal weight during self-administration. d Average number of active lever presses during the last 3 days of SA (left), during the last 2 days of extinction (middle), and during the TMT-induced reinstatement test. (**p < 0.01 Sal-PE 10-day Sal vs. TMT-PE 10-day Sal, ****p < 0.0001, TMT-PE 10-day Sal vs. TMT-PE 10-day OXT). Mean +/ −SEM; n = 7-8 per group pre-exposed to TMT 3 (Experiment 1) or 5 weeks (Experiment 2) before. TMT pre-exposure exacerbated TMT-induced reinstatement of drug-seeking, suggesting that repeated exposure to a predator threat, has an enduring ability to exacerbate drug-seeking induced by the same threat but does not assume that the rats sustained a general exacerbation of stress responsivity. In Experiment 1, a single injection of OXT 30 min prior to reinstatement attenuated stress-induced METH-seeking regardless of TMT pre-exposure. In contrast, 10 days of OXT injections suppressed reinstatement in TMT-PE rats only, suggesting that OXT can reduce drug-seeking by attenuating the enduring effects of repeated TMT exposure. Pre-exposure to TMT had no effect on acquisition or maintenance of METH SA either when the exposure occurred immediately prior to acquisition of METH SA (Experiment 1) or following a delay of 10 days (Experiment 2). This finding is consistent with a report that neither non-contingent electric footshock nor injection of CORT immediately prior to initiating METH SA had an effect on acquisition (Moffett and Goeders 2005) . In general, the effects of stress pre-exposure on the effects of abused drugs depend largely on the type of stressor, its severity, and the pattern and duration of exposure (see Introduction and Yap and Miczek 2008) . Also, a different self-administration paradigm that more precisely tests an animal's motivation to self-administer METH (Hicks et al. 2014) may be more sensitive to TMT pre-exposure. In Experiment 2, there also was no effect of TMT pre-exposure or OXT injections on acquisition or maintenance of METH SA. Similarly, acquisition of METH SA on an FR1 schedule was not altered in female rats treated repeatedly as adolescents (12 weeks earlier) with 1 mg/kg OXT (Hicks et al. 2014) ; however, under a progressive ratio schedule of reinforcement, OXT pretreatment reduced the motivation to self-administer METH and suppressed METH-primed reinstatement in that study.
The finding that repeated exposure to a predator odor potentiated reinstatement of drug-seeking suggests that sensitization developed in pre-stressed rats and persisted for 3-5 weeks. Sensitization to a variety of anxiety-producing stimuli is a hallmark of hyperarousal in PTSD patients (Dykman et al. 1997 ) that is modeled in preclinical PTSD paradigms such as stress-enhanced fear learning (Rau et al. 2005) . Behavioral sensitization has been shown to result from exposure to various stressors followed by an acute non-contingent psychostimulant challenge (Eagle and Perrine 2013; Toledano et al. 2013) or augmented drug-seeking on a progressive ratio reinforcement schedule .
The finding that an injection of OXT 30 min prior to testing blocked TMT-induced reinstatement confirms previous reports that this dose suppresses reinstatement induced by METH-associated cues, a METH-prime, or yohimbine (Carson et al. 2010; Cox et al. 2013) . However, this is the first study to examine the effects of OXT on reinstatement of drugseeking exacerbated by pre-exposure to a stressor. The fact that a single systemic dose of OXT decreased TMT-induced reinstatement in all rats in Experiment 1 reinforces the idea that mechanisms underlying both stress and drug-seeking are attenuated by OXT when it is injected on the day of reinstatement testing. Reinstatement of drug-seeking is thought to depend on disturbed glutamate transmission in the dorsomedial PFC-NAc pathway (Parsegian and See 2014) . Thus, it is possible that administration of OXT acts via OXTRs in brain regions such as the PFC or NAc ) to suppress reinstatement of METH-seeking. In fact, OXTRs in the PFC of mice are expressed exclusively in GABAsomatostatin interneurons and bath application of OXT in PFC slices increases the firing of these neurons (Nakajima et al. 2014 ) that suppresses pyramidal neuron activity. Further, OXT infusion into the medial PFC blocks restraint stressinduced reinstatement of METH-induced conditioned place preference in a glutamate-dependent fashion (Carson et al. 2010; Han et al. 2014) . Similarly, stress-induced behavioral cross-sensitization to stimulants is blocked by glutamate receptor antagonists (Yap et al. 2005) .
OXT exerted significant effects on stress-induced reinstatement of drug-seeking only in rats with a history of TMT exposure in Experiment 2. This finding is consistent with other studies that have shown that repeated administration of OXT exerts long-lasting effects on drug-taking and drug-seeking (Bowen et al. 2011; Hicks et al. 2014) as well as behavioral (Slattery and Neumann 2010) and physiological measures (Petersson et al. 1996; Petersson et al. 1999 ) of anxiety. In this regard, there is evidence that repeated stimulation of the hypothalamic OXT neuronal system enhances its cellular and synaptic plasticity by inducing cellular hypertrophy, OXT and OXTR synthesis, and OXT release (Theodosis 2002) . The duration of this functional augmentation depends on the intensity and duration of stimulation of the endogenous system. Importantly, repeated exogenous OXT administration stimulates OXT neuronal functionality (Petersson et al. 1999 ) which may lead to persistent changes in behavior that affect subsequent stress reactivity. Thus, it is possible that OXT administration after repeated stress exposure decreases vulnerability to stress-induced addictive drug-seeking and drug-taking for an extended period of time, promoting OXT as a therapeutic agent with significant implications for individuals with a dual diagnosis of PTSD and SUD.
Possible mechanisms underlying the ability of exogenous OXT to suppress interactions between stress and METHseeking include both suppression of the HPA axis and direct CNS effects. However, it is not likely that peripheral CORT mediated the OXT effects in this study because OXT increased plasma CORT levels in TMT-PE rats in Experiment 1 and suppressed CORT levels in Experiment 2 regardless of TMT pre-exposure. Systemic injections of OXT have divergent effects on CORT levels depending on the timing; acute OXT increased basal CORT levels 30 min but not 2 h after systemic injection whereas 5 days of OXT injections decreased CORT levels for an extended period of time-up to 10 days later (Petersson et al. 1999) . Regarding direct effects of systemic OXT on the CNS, it is estimated that 0.2 % of exogenous OXT enters the brain after systemic administration (Neumann et al. 2013 ) and presumably stimulates OXT receptors in the CNS (Neumann and Landgraf 2012) . Oxytocin receptors are abundant in several brain regions that are associated with emotional triggers of drug-seeking as well as stress, including the prefrontal cortex, hypothalamus, and amygdala (Smeltzer et al. 2006) , and chronic METH administration alters OXTR levels in several of these brain areas (Zanos et al. 2014) . Future studies will address how peripheral administration of OXT affects both the HPA axis and the central OXTR system.
In conclusion, the present study demonstrates that preexposure to an ethologically-relevant stressor, TMT, exacerbated METH-seeking elicited by re-exposure to that stressor weeks later. Acute exposure to OXT administered prior to reinstatement prevented drug-seeking induced by the TMT stressor in all animals regardless of stress history. However, chronic administration of OXT after the initial TMT exposure selectively prevented the exacerbated stress-induced drugseeking only in animals with a history of TMT exposure. This evidence provides significant preclinical foundation for the use of OXT as a novel therapeutic drug in patients with comorbid METH-and stress-induced PTSD symptomatology.
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